The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Open accessAbstract
BACKGROUND: Some 50% of patients with visceral leishmaniasis (kala-azar) worldwide live in the Indian state of Bihar. Liposomal amphotericin B is an effective treatment when administered in short courses. We wanted to determine whether the efficacy of a single infusion of liposomal amphotericin B was inferior to conventional parenteral therapy, consisting of 15 alternate-day infusions of amphotericin B deoxycholate. METHODS: In this open-label study, we randomly assigned 412 patients in a 3:1 ratio to receive either liposomal amphotericin B (liposomal-therapy group) or amphotericin B deoxycholate (conventional-therapy group). Liposomal amphotericin B (at a dose of 10 mg per kilogram of body weight) was given once, and patients were discharged home 24 hours later. Amphotericin B deoxycholate, which was administered in 15 infusions of 1 mg per kilogram, was given every other day during a 29-day hospitalization. We determined the cure rate 6 months after treatment. RESULTS: A total of 410 patients--304 of 304 patients (100%) in the liposomal-therapy group and 106 of 108 patients (98%) in the conventional-therapy group--had apparent cure responses at day 30. Cure rates at 6 months were similar in the two groups: 95.7% (95% confidence interval [CI], 93.4 to 97.9) in the liposomal-therapy group and 96.3% (95% CI, 92.6 to 99.9) in the conventional-therapy group. Adverse events in the liposomal-therapy group were infusion-related fever or rigors (in 40%) and increased anemia or thrombocytopenia (in 2%); such events in the conventional-therapy group were fever or rigors (in 64%), increased anemia (in 19%), and hypokalemia (in 2%). Nephrotoxicity or hepatotoxicity developed in no more than 1% of patients in each group. CONCLUSIONS: A single infusion of liposomal amphotericin B was not inferior to and was less expensive than conventional therapy with amphotericin B deoxycholate. (ClinicalTrials.gov number, NCT00628719.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, H. W., Berman, J. D., Davies, C. R., & Saravia, N. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67629-5 · Cited by 1,771
Self-citationOral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Self-citationInjectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Self-citationWalsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis
Bhattacharya, S. K., Sinha, P. K., Sundar, S., Thakur, C. P., Jha, T. K., Pandey, K., Das, V. R., Kumar, N., Lal, C., Verma, N., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/519690 · Cited by 261
Self-citationSundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209
Self-citationAmphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Sundar, S., Mehta, H., Suresh, A. V., Singh, S. P., Rai, M., & Murray, H. W. (2004) · Clinical Infectious Diseases · doi:10.1086/380971 · Cited by 189
Self-citationSundar, S., Lockwood, D. N. J., Agrawal, G., Rai, M., Makharia, M. K., & Murray, H. W. (2001) · BMJ · doi:10.1136/bmj.323.7310.419 · Cited by 165
Self-citationSundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V. P., & Buffels, R. (2003) · Clinical Infectious Diseases · doi:10.1086/377542 · Cited by 134
Self-citationMondal, D., Singh, S. P., Kumar, N., Joshi, A. B., Sundar, S., Das, P., Hirve, S. S., Kroeger, A., & Boelaert, M. (2009) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000355 · Cited by 131
Self-citationLow-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
Sundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V., & Buffels, R. (2002) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2002.66.143 · Cited by 98
Self-citationSyriopoulou, V., Daikos, G. L., Theodoridou, M., Pavlopoulou, I. D., Manolaki, A. G., Sereti, E., Karamboula, A., Papathanasiou, D., Krikos, X., & Saroglou, G. (2003) · Clinical Infectious Diseases · doi:10.1086/367843 · Cited by 86
Thakur, C. P. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00312-5 · Cited by 61
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis
Murray, H. W. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.2.279 · Cited by 61
Self-citationEffect of tissue penetration on AmBisome efficacy.
Adler‐Moore, J., & Proffitt, R. T. (2003) · PubMed · Cited by 48
Cited by
Burza, S., Croft, S. L., & Boelaert, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31204-2 · Cited by 1,913
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“Another trial of 304 patients found non-inferiority of LAmB (10 mg/kg) compared to DAmB (15 mg/kg total dose; 1 mg/kg alternate days for 30 days) [110].”
Metadata
- Authors
- Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-02-11
- Volume
- 362
- Issue
- 6
- Pages
- 504-512
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2072809427
- Cited by
- 434
- References
- 15
- FWCI
- 39.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.